Profiling of normal and malignant breast tissue show CD44high/CD24low phenotype as a predominant stem/progenitor marker when used in combination with Ep-CAM/CD49f markers

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Ghebeh, Hazem ^a,b   Sleiman, Ghida Majed ^a   Manogaran, Pulicat S ^a   Al Mazrou, Amer ^a   Barhoush, Eman ^a   Al Mohanna, Falah H ^a   Tulbah, Asma ^a   Al Faqeeh, Khalid ^a   Adra, Chaker N ^a,c  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b ALFAISAL UNIVERSITY   (Saudi Arabia)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

ALDH; Breast cancer; CD10; CD44high CD24low; Flow cytometry; Mammary gland; MUC 1; Normal breast; Stem cells

Indexed keywords

ALPHA6 INTEGRIN; CD24 ANTIGEN; EPITHELIAL CELL ADHESION MOLECULE; HERMES ANTIGEN; TUMOR MARKER; CELL ADHESION MOLECULE; TRANSCRIPTOME; TUMOR ANTIGEN; TUMOR-ASSOCIATED ANTIGEN GA733;

ADULT; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL; CANCER STEM CELL; CELL CULTURE; CELL FUNCTION; CELL SELECTION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; PHENOTYPE; STEM CELL; ANIMAL; BIOSYNTHESIS; BREAST TUMOR; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; METABOLISM; MOUSE; PATHOLOGY; XENOGRAFT;

ANIMALS; ANTIGENS, CD24; ANTIGENS, CD44; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CELL ADHESION MOLECULES; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; INTEGRIN ALPHA6; MICE; NEOPLASTIC STEM CELLS; PHENOTYPE; TRANSCRIPTOME; TRANSPLANTATION, HETEROLOGOUS; TUMOR MARKERS, BIOLOGICAL;

EID: 84878893949     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-289     Document Type: Article

References (34)

1. Frank NY, Margaryan A, Huang Y, Schatton T, Waaga-Gasser AM, Gasser M, Sayegh MH, Sadee W, Frank MH. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Canc Res 2005, 65(10):4320-4333.
2. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Canc Inst 2008, 100(9):672-679.
3. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444(7120):756-760. 10.1038/nature05236, 17051156.
4. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Canc 2008, 8(10):755-768.
5. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003, 100(7):3983-3988. 10.1073/pnas.0530291100, 153034, 12629218.
6. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1(5):555-567. 10.1016/j.stem.2007.08.014, 2423808, 18371393.
7. Bachelard-Cascales E, Chapellier M, Delay E, Pochon G, Voeltzel T, Puisieux A, Caron de Fromentel C, Maguer-Satta V. The CD10 enzyme is a key player to identify and regulate human mammary stem cells. Stem Cells 2010, 28(6):1081-1088. http://www.ncbi.nlm.nih.gov/pubmed/20506111, 10.1002/stem.435, 20506111.
8. Eirew P, Stingl J, Raouf A, Turashvili G, Aparicio S, Emerman JT, Eaves CJ. A method for quantifying normal human mammary epithelial stem cells with in vivo regenerative ability. Nat Med 2008, 14(12):1384-1389. 10.1038/nm.1791, 19029987.
9. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ, Wicha MS. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 2003, 17(10):1253-1270. 10.1101/gad.1061803, 196056, 12756227.
10. Stingl J, Raouf A, Emerman JT, Eaves CJ. Epithelial progenitors in the normal human mammary gland. J Mammary Gland Biol Neoplasia 2005, 10(1):49-59. 10.1007/s10911-005-2540-7, 15886886.
11. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, Asselin-Labat ML, Gyorki DE, Ward T, Partanen A, et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 2009, 15(8):907-913. 10.1038/nm.2000, 19648928.
12. Alexander CM, Puchalski J, Klos KS, Badders N, Ailles L, Kim CF, Dirks P, Smalley MJ. Separating stem cells by flow cytometry: reducing variability for solid tissues. Cell Stem Cell 2009, 5(6):579-583. 10.1016/j.stem.2009.11.008, 3076188, 19951686.
13. Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Canc Res 2008, 10(2):R25.
14. Ghebeh H, Mohammed S, Al-Omair A, Qattan A, Lehe C, Al-Qudaihi G, Elkum N, Alshabanah M, Bin Amer S, Tulbah A, et al. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 2006, 8(3):190-198. 10.1593/neo.05733, 1578520, 16611412.
15. Ghebeh H, Tulbah A, Mohammed S, Elkum N, Bin Amer SM, Al-Tweigeri T, Dermime S. Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells. Int J Canc 2007, 121(4):751-758.
16. Wang CS, Goulet F, Lavoie J, Drouin R, Auger F, Champetier S, Germain L, Tetu B. Establishment and characterization of a new cell line derived from a human primary breast carcinoma. Canc Genet Cytogenet 2000, 120(1):58-72.
17. Clarke RB, Howell A, Potten CS, Anderson E. Dissociation between steroid receptor expression and cell proliferation in the human breast. Canc Res 1997, 57(22):4987-4991.
18. Stingl J. Detection and analysis of mammary gland stem cells. J Pathol 2009, 217(2):229-241. 10.1002/path.2457, 19009588.
19. Bachelard-Cascales E, Chapellier M, Delay E, Pochon G, Voeltzel T, Puisieux A, Caron De Fromentel C, Maguer-Satta V. The CD10 enzyme is a key player to identify and regulate human mammary stem cells. Stem Cells 2010, 28(6):1081-1088. 10.1002/stem.435, 20506111.
20. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M, et al. Molecular definition of breast tumor heterogeneity. Canc Cell 2007, 11(3):259-273.
21. Abraham BK, Fritz P, McClellan M, Hauptvogel P, Athelogou M, Brauch H. Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Canc Res 2005, 11(3):1154-1159.
22. Mylona E, Giannopoulou I, Fasomytakis E, Nomikos A, Magkou C, Bakarakos P, Nakopoulou L. The clinicopathologic and prognostic significance of CD44+/CD24(-/low) and CD44-/CD24+ tumor cells in invasive breast carcinomas. Hum Pathol 2008, 39(7):1096-1102. 10.1016/j.humpath.2007.12.003, 18495204.
23. Ahmed MA, Aleskandarany MA, Rakha EA, Moustafa RZ, Benhasouna A, Nolan C, Green AR, Ilyas M, Ellis IO. A CD44(-)/CD24(+) phenotype is a poor prognostic marker in early invasive breast cancer. Breast Canc Res Treat 2012, 133(3):979-995.
24. Cariati M, Naderi A, Brown JP, Smalley MJ, Pinder SE, Caldas C, Purushotham AD. Alpha-6 integrin is necessary for the tumourigenicity of a stem cell-like subpopulation within the MCF7 breast cancer cell line. Int J Canc 2008, 122(2):298-304.
25. Ali HR, Dawson SJ, Blows FM, Provenzano E, Pharoah PD, Caldas C. Cancer stem cell markers in breast cancer: pathological, clinical and prognostic significance. Breast Canc Res 2011, 13(6):R118.
26. Shehata M, Teschendorff A, Sharp G, Novcic N, Russell IA, Avril S, Prater M, Eirew P, Caldas C, Watson CJ. Phenotypic and functional characterisation of the luminal cell hierarchy of the mammary gland. Breast Canc Res 2012, 14(5):R134.
27. Gusterson BA, Warburton MJ, Mitchell D, Ellison M, Neville AM, Rudland PS. Distribution of myoepithelial cells and basement membrane proteins in the normal breast and in benign and malignant breast diseases. Canc Res 1982, 42(11):4763-4770.
28. Kalof AN, Tam D, Beatty B, Cooper K. Immunostaining patterns of myoepithelial cells in breast lesions: a comparison of CD10 and smooth muscle myosin heavy chain. J Clin Pathol 2004, 57(6):625-629. 10.1136/jcp.2003.013227, 1770324, 15166269.
29. Ince TA, Richardson AL, Bell GW, Saitoh M, Godar S, Karnoub AE, Iglehart JD, Weinberg RA. Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes. Canc Cell 2007, 12(2):160-170.
30. Keller PJ, Arendt LM, Skibinski A, Logvinenko T, Klebba I, Dong S, Smith AE, Prat A, Perou CM, Gilmore H, et al. Defining the cellular precursors to human breast cancer. Proc Natl Acad Sci USA 2012, 109(8):2772-2777. 10.1073/pnas.1017626108, 3286919, 21940501.
31. Molyneux G, Geyer FC, Magnay FA, McCarthy A, Kendrick H, Natrajan R, Mackay A, Grigoriadis A, Tutt A, Ashworth A, et al. BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell 2010, 7(3):403-417. 10.1016/j.stem.2010.07.010, 20804975.
32. Lo PK, Kanojia D, Liu X, Singh UP, Berger FG, Wang Q, Chen H. CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFbeta signaling. Oncogene 2012, 31(21):2614-2626. 10.1038/onc.2011.439, 3260386, 21996747.
33. Bankfalvi A, Terpe HJ, Breukelmann D, Bier B, Rempe D, Pschadka G, Krech R, Lelle RJ, Boecker W. Immunophenotypic and prognostic analysis of E-cadherin and beta-catenin expression during breast carcinogenesis and tumour progression: a comparative study with CD44. Histopathology 1999, 34(1):25-34. 10.1046/j.1365-2559.1999.00540.x, 9934581.
34. Fillmore C, Kuperwasser C. Human breast cancer stem cell markers CD44 and CD24: enriching for cells with functional properties in mice or in man?. Breast Canc Res 2007, 9(3):303.